Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 35: 787-793, 1989;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chandler, W. L.
Right arrow Articles by Stratton, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chandler, W. L.
Right arrow Articles by Stratton, J. R.

Clinical Chemistry, Vol 35, 787-793, Copyright © 1989 by American Association for Clinical Chemistry

Standardization of methods for measuring plasminogen activator inhibitor activity in human plasma

WL Chandler, SC Loo, SV Nguyen, G Schmer and JR Stratton
Department of Laboratory Medicine, University of Washington, Seattle 98195.

We have standardized the measurement of plasminogen activator inhibitor type 1 (PAI-1) activity in plasma. One-chain tissue-type plasminogen activator (t-PA; EC 3.4.21.31; final activity, 5 int. units/mL) was incubated with plasma (final dilutions 1:4 to 1:40) in phosphate buffer (pH 7.4, ionic strength = 0.15) for 15 min at 37 degrees C, followed by acidification and measurement of residual t-PA activity by an amidolytic method. The PAI-1 activity assay was 98% specific for PAI-1 activity in samples from both pregnancy and nonpregnancy, and varied linearly with added plasma volume when the percent inhibition of t-PA was between 8% and 50%. For the standardized method, analytical recovery was 93 +/- 5%, the detection limit was 1.6 arbitrary units per milliliter (1 arb. unit of PAI-1 activity = inhibition of 1 int. unit of t-PA activity), and total imprecision was 10.2 (SD 0.7) arb. units/mL (CV = 7%, n = 20). The average PAI-1 activity in 10 healthy individuals drawn between 0800 and 1000 hours was 23.9 +/- 15.4 arb. units/mL. Compared with the standardized assay, two of three previously described assays underestimated PAI-1 activity in plasma by 77% and 85%, respectively.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
T. Ono, M. Sogabe, M. Ogura, and F. Furusaki
Automated Latex Photometric Immunoassay for Total Plasminogen Activator Inhibitor-1 in Plasma
Clin. Chem., June 1, 2003; 49(6): 987 - 989.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
A.L. Komarov, E.P. Panchenko, A.B. Dobrovolsky, Yu.A. Karpov, A.D. Deev, E.V. Titaeva, K.K. Davletov, A.R. Eshkeeva, and L.A. Markova
D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease
Eur. Heart J., August 2, 2002; 23(16): 1309 - 1316.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
A. W. Gardner and L. A. Killewich
Association Between Physical Activity and Endogenous Fibrinolysis in Peripheral Arterial Disease: A Cross-sectional Study
Angiology, July 1, 2002; 53(4): 367 - 374.
[Abstract] [PDF]

Home page
 ANGIOLOGYHome page
E. Panchenko, A. Eshkeeva, A. Dobrovolsky, E. Titaeva, Ya. Podinovskaya, K.M.A. Hussain, Yu. Karpov, and E. Panchenko
Effects of Indobufen and Pentoxifylline on Walking Capacity and Hemostasis in Patients with Intermittent Claudication: Results of Six Months of Treatment
Angiology, March 1, 1997; 48(3): 247 - 254.
[Abstract] [PDF]

Home page
 HypertensionHome page
C. A. DeSouza, D. R. Dengel, M. A. Rogers, K. Cox, and R. F. Macko
The Fibrinolytic System Is Not Impaired in Older Men With Hypertension
Hypertension, May 1, 1996; 27(5): 1053 - 1058.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
E. T. Stevenson, K. P. Davy, and D. R. Seals
Hemostatic, Metabolic, and Androgenic Risk Factors for Coronary Heart Disease in Physically Active and Less Active Postmenopausal Women
Arterioscler Thromb Vasc Biol, May 1, 1995; 15(5): 669 - 677.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1989 by the American Association for Clinical Chemistry.